Navigation Links
Abbott's Humira(r) (Adalimumab) Gets Approval by EU for Crohn's Disease Treatment

ABBOTT PARK, Ill., Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA(R) (adalimumab) as a treatment for severe Crohn's disease. HUMIRA is the first self-administered biologic for the treatment of Crohn's disease and offers an effective and convenient treatment option that can help enable patients to maintain control of their disease. This announcement follows FDA approval for the Crohn's disease indication, which Abbott received in February, and is the fourth approved indication for HUMIRA in the United States and the European Union.

Crohn's disease is a serious, chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than 1 million people in North America and Europe. It affects people of all ages, but it is primarily a disease of young adults, with onset typically before age 40. There is no medical or surgical cure for Crohn's disease and few treatment options exist for patients suffering with this chronic condition.

"Crohn's can have a devastating impact on patients, many of whom are young and active, making it difficult to carry out normal day-to-day activities," said Rod Mitchell, chairman, European Federation of Crohn's & Ulcerative Colitis Associations. "The unpredictable nature of the disease can seriously impact their quality of life and self-esteem. For the half million people across Europe suffering from Crohn's, this approval offers hope to help them regain control of their disease."

Common symptoms of Crohn's disease include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases, rectal bleeding. Complications include intestinal obstruction, fistulas (ulcers that form tunnels to surrounding tissues), and malnutrition. Over the course of their disease, as many as 75 percent of patients with Crohn's disease will undergo surgery at least once for complications or disease resistant to treatment. Of thos e who undergo surgery to remove a portion of the intestines (resection), half will experience a relapse within five years.

"After I was diagnosed with Crohn's, the unpredictable symptoms made working and relationships difficult. I was afraid to leave the house," said Rocio Lopez, a HUMIRA clinical trial patient. "With HUMIRA, my Crohn's symptoms are under control and I have more freedom to live my life."

"The approval of HUMIRA in Crohn's disease means that an underserved patient population now has a clinically effective treatment option that they can administer themselves," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development at Abbott. "For the thousands of people across Europe with Crohn's disease, HUMIRA represents a new, effective, and convenient treatment option."


'"/>




Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don suffered from severe injury ... author was able to successfully recover. In “ Origin & Insertion Charts for Massage ... on the principals of massage, anatomy , trigger points and referral pain ...
(Date:2/22/2017)... New York, NY (PRWEB) , ... February 22, ... ... academics, professional life and athletics. It’s enough to overwork even the sharpest brain. ... ingredients that offer peak healthy activity without over clocking the brain. Each capsule ...
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... medical detox treatment to the thousands of individuals who have recently fallen victim to ... accredited hospital in Orange County, California, where they are free from the shame, ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the ... once again feature Heroes On The Water (HOW), a non-profit organization dedicated to helping ... episode has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish ...
(Date:2/22/2017)... ... 2017 , ... In a 2012 survey, over a quarter ... a prescription because they could not afford to pay for it. Among those ... At the same time, hospitals, pharmacies, manufacturers and nursing homes dispose ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... report its fourth quarter and full year 2016 financial ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... event can be obtained as follows: Thursday, ...
(Date:2/22/2017)... 22, 2017 General Report Contents - ... & Growth Trends - Market Drivers & Limiters ... each chapter segment - Section on recent mergers ... https://www.reportbuyer.com/product/4665946/ This market comprises ... articulated arm lasers, fiber-delivered lasers and direct delivery ...
(Date:2/22/2017)... -- a condition where an organ of the ... weak abdominal wall. Hernia is classified into five ... hernia, umbilical hernia, and other (hiatal hernia and ... performed using a mesh, made-up of biological or ... the available options, open tension-free repair procedures and ...
Breaking Medicine Technology: